Progress in clinical immunotherapy for tumors.
Immunotherapy of human tumors is a promising new modality that remains highly investigational and poses unforeseen risks. It should preferably be conducted in patients brought into remission by conventional antitumor therapy and against the background of a complex, reliable monitoring system capable of quantitatively measuring the patient's antitumor immune reactions.